Designing a new vaccine to fight HIV
Official title: Project 1: Immunogen Design and Delivery
Funded at Scripps Research Institute, the · NIH-11076801 · Data updated 2026-11-12
This study is testing a new vaccine for HIV that aims to help your body make powerful antibodies by focusing on special B cells, and if you join, you'll help us see how well this vaccine works in boosting your immune response.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | June 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $428,319 |
| NIH project number | 5P01AI177683-03 |
| Project ID | NIH-11076801 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation would include individuals at high risk for HIV or those living with HIV who are interested in new treatment options.
✕Less likely to help
Patients who are not at risk for HIV or those who have already developed resistance to current treatments may not benefit from this research.
What this research studies
This research focuses on creating an effective vaccine for HIV by targeting specific B cells that can produce broadly neutralizing antibodies (bnAbs). The approach involves using specially designed immunogens to activate and expand these rare B cell precursors, which are crucial for generating a strong immune response against HIV. The project will utilize a combination of priming and boosting strategies to enhance the effectiveness of the vaccine. Patients may be involved in trials that assess the immune response generated by these novel immunogens.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking vaccine that provides effective protection against HIV infection.
How similar studies have gone: While there have been various approaches to HIV vaccine development, this specific strategy of targeting rare B cell precursors with germline-targeting immunogens is relatively novel and has not been extensively tested.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Andrabi, Raiees Ahmad — Scripps Research Institute, the
- Study coordinator: Andrabi, Raiees Ahmad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.